Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-7753.22%
operating margin TTM
-7857.88%
revenue TTM
193.95 Thousand
revenue per share TTM
0.04$
valuation ratios | |
|---|---|
| pe ratio | -0.45 |
| peg ratio | -0.02 |
| price to book ratio | 0.35 |
| price to sales ratio | 49.28 |
| enterprise value multiple | -1.67 |
| price fair value | 0.35 |
profitability ratios | |
|---|---|
| gross profit margin | 39.59% |
| operating profit margin | -7857.88% |
| pretax profit margin | -7915.62% |
| net profit margin | -7753.22% |
| return on assets | -69.68% |
| return on equity | -93.93% |
| return on capital employed | -76.23% |
liquidity ratio | |
|---|---|
| current ratio | 11.58 |
| quick ratio | 11.20 |
| cash ratio | 10.50 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 1,860.09 |
| operating cycle | 1,870.24 |
| days of payables outstanding | 846.72 |
| cash conversion cycle | 1,023.52 |
| receivables turnover | 35.95 |
| payables turnover | 0.43 |
| inventory turnover | 0.20 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.06 |
| debt equity ratio | 0.07 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.07 |
| interest coverage | -397.83 |
| cash flow to debt ratio | -7.80 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.75 |
| cash per share | 2.38 |
| operating cash flow per share | -1.52 |
| free cash flow operating cash flow ratio | 1.15 |
| cash flow coverage ratios | -7.80 |
| short term coverage ratios | -21.14 |
| capital expenditure coverage ratio | -6.65 |
Frequently Asked Questions
When was the last time Virax Biolabs Group Limited (NASDAQ:VRAX) reported earnings?
Virax Biolabs Group Limited (VRAX) published its most recent earnings results on 20-11-2024.
What is Virax Biolabs Group Limited's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Virax Biolabs Group Limited (NASDAQ:VRAX)'s trailing twelve months ROE is -93.93%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Virax Biolabs Group Limited (VRAX) currently has a ROA of -69.68%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did VRAX's net profit margin stand at?
VRAX reported a profit margin of -7753.22% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is VRAX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 11.58 in the most recent quarter. The quick ratio stood at 11.20, with a Debt/Eq ratio of 0.07.